



NC DEPARTMENT OF HEALTH AND HUMAN SERVICES

NC MEDICAID DIVISION OF HEALTH BENEFITS PREFERRED DRUG LIST REVIEW PANEL MEETING

AGENDA

Thursday, October 9, 2025, 1:00 p.m.– 5:00 p.m.
Virtual Online Meeting

- I. Welcome
- II. Introductions / Medicaid Updates
- III. Overview of Panel Activities and Procedures
- IV. Drug Class Reviews, Review of Public Comments and Public Testimony

As a reminder, the PDL Panel meets once per quarter to make proposed changes. Additionally, every PDL category is reviewed at least once per calendar year. Public comments during the 30-day public comment period are allowed for categories that the State designates on the publicly posted document (any category with proposed additions and/or removals). Speakers at the PDL Panel meeting are only allowed for categories listed on the agenda for that meeting. **The categories below contain recommendations that will require a vote by the PDL Panel. Those categories that are highlighted have no State recommendations but are open for discussion:**

ANALGESICS

1. Short Acting Schedule III-IV opioids/Analgesic Combinations
2. Neuropathic Pain

ANTICONSULSANTS

1. Carbamazepine Derivatives
2. First Generation
3. Second Generation

ANTI-INFECTIVES – SYSTEMIC

1. Tetracycline Derivatives

BEHAVIORAL HEALTH

1. Selective Serotonin Reuptake Inhibitor (SSRI)

CARDIOVASCULAR

1. Cholesterol Lowering Agents
2. Coronary Vasodilators
3. Endothelin Receptor Antagonists
4. Inhaled Prostacyclin Analogs
5. Niacin Derivatives
6. Nitrate Combination
7. Platelet Inhibitors
8. Sympatholytics And Combinations
9. Cardiovascular, Other

CENTRAL NERVOUS SYSTEM

1. Antimigraine Agents (CGRP Blocker/Modulators Preventative)
2. Tobacco Cessation

ENDOCRINOLOGY

1. Hypoglycemics – Injectable Rapid Acting Insulin Intermediate Acting Insulin
2. Short Acting Insulin
3. GLP-1 Receptor Agonists and Combinations indicated for the treatment of Diabetes
4. Hypoglycemics – Oral 2nd Generation Sulfonylureas
5. DPP-IV Inhibitors and Combinations
6. Meglitinides
7. SGLT-2 Inhibitors and Combinations

GASTROINTESTINAL

1. Bile Acid Salts

GENITOURINARY/RENAL

1. Benign Prostatic Hyperplasia Treatments

HEMATOLOGICS

1. Colony Stimulating Factors
2. Thrombopoiesis Stimulating Agents

OPHTHALMIC

1. Allergic Conjunctivitis Agents
2. Antibiotics
3. Anti-inflammatory / Immunomodulator
4. Carbonic Anhydrase Inhibitors/Combinations

OSTEOPOROSIS

1. Bone Resorption Suppression and Related Agents

TOPICALS

1. Acne Agents
2. NSAIDS
3. Antiparasitics
4. Psoriasis
5. Rosacea Agents
6. Steroids (Low Potency)
7. Steroids (Medium Potency)
8. Steroids (Very High Potency)

MISCELLANEOUS

1. Urea Cycle Disorder Treatments, Oral
2. Weight Management Agents (Non-Incretin Mimetics)
3. Immunomodulators, Atopic Dermatitis
4. Estrogen Agents, Combinations
5. Glucocorticoid Steroids, Oral
6. Cytokine And Cam Antagonists
7. Disposable Insulin Delivery Devices

Labeler Termination

1. Drugs that are no longer Rebatable

V. Closing comments and adjournment